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Abstract: The beneficial effects exerted by levosimendan against cardiac failure could be related to 
the modulation of oxidative balance. We aimed to examine the effects of levosimendan in patients 
with cardiogenic shock or low cardiac output on cardiac systo-diastolic function and plasma 
oxidants/antioxidants (glutathione, GSH; thiobarbituric acid reactive substances, TBARS). In four 
patients undergoing coronary artery bypass grafting or angioplasty, cardiovascular parameters and 
plasma GSH and TBARS were measured at T0 (before levosimendan infusion), T1 (1 h after the 
achievement of the therapeutic dosage of levosimendan), T2 (end of levosimendan infusion), T3 (72 
h after the end of levosimendan infusion), and T4 (end of cardiogenic shock). We found an 
improvement in the indices of systolic (ejection fraction, cardiac output, cardiac index) and diastolic 
(E to early diastolic mitral annular tissue velocity, E/’; early to late diastolic transmitral flow velocity, 
EA) cardiac function at early T2. A reduction of central venous pressure and pulmonary wedge 
pressure was also observed. Plasma levels of GSH and TBARS were restored by levosimendan at 
T1, as well. The results obtained indicate that levosimendan administration can regulate 
oxidant/antioxidant balance as an early effect in cardiogenic shock/low cardiac output patients. 
Modulation of oxidative status on a mitochondrial level could thus play a role in exerting the cardio-
protection exerted by levosimendan in these patients. 
Keywords: antioxidants; calcium sensitizer; heart failure; mitochondria function; peroxidation 
 
1. Introduction 
Levosimendan is an inotrope used for the treatment of acutely decompensated heart failure 
patients with low cardiac output or cardiogenic shock [1–4]. 
Among its mechanisms of action, the sensitization of cardiac troponin C to calcium in cardiac 
muscle [5–7] and the opening adenosine triphosphate-sensitive potassium (KATP) channels in vascular 
smooth muscle cells [8,9] have been described. Due to these pharmacological actions, levosimendan 
improves atrio-ventricular coupling and cardiac mechanical efficiency without increasing 
myocardial oxygen consumption [10–13]. Moreover, levosimendan has been shown to have a direct 
effect on mitochondria [14–19]. 
Preliminary data obtained in vitro, ex vivo, and in vivo in animal models have shown that 
levosimendan could improve endothelial and mitochondrial function, and protect against 
peroxidation, as well. In anesthetized pigs subjected to renal ischemia/reperfusion, the intrarenal 
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levosimendan administration was able to increase renal function and keep the oxidant balance, as 
shown by the increased plasma levels of glutathione (GSH) and the reduced release of peroxidation 
markers, like thiobarbituric acid reactive substances (TBARS) [20]. Similar nominally beneficial 
effects against peroxidation were observed in anesthetized rats subjected to hepatic 
ischemia/reperfusion and treated with levosimendan [21]. 
TBARS, which reflect the release of malon(MDA) generated through the peroxidation of 
polyunsaturated fatty acids, have been widely adopted as indicators of oxidative stress in various 
cardiovascular diseases [22]. GSH plays an important role in the maintenance of the thiol-redox status 
of the cell, and for this reason could act as antioxidant. GSH deficiency might manifest itself through 
an increased susceptibility to oxidative stress and to the augmented onset and progression of many 
diseases, including the cardiovascular diseases [23].) 
Similar beneficial effects against peroxidation, as were observed in the renal model of 
ischemia/reperfusion, have been observed in anesthetized rats subjected to hepatic 
ischemia/reperfusion and treated with levosimendan [21]. Finally, in rat hepatocytes, the 
administration of levosimendan dose-dependently counteracted the injuries caused by oxidative 
stress, as evidenced by the keeping GSH content and the reduction of TBARS release [24]. In all the 
above conditions, endothelial and mitochondrial function were found to be ameliorated by 
levosimendan, which prevented the fall of mitochondrial membrane potential and restored nitric 
oxide (NO) release. 
The beneficial effects elicited by levosimendan against oxidative stress could represent a further 
mechanism of protection in heart failure (HF) patients. The implication of oxidative stress in the 
pathophysiology of HF is well established. Oxidative stress may impair cardiac functions through 
damage to the cellular proteins and membranes by initiation of lipid peroxidation, thereby inducing 
cellular death and apoptosis. Moreover, it could exert direct negative inotropic effects through the 
reduction of cytosolic intracellular free calcium [25]. Thus, there is strong circumstantial evidence 
that oxidative stress is a prognostic factor in HF patients. Keith et al. showed that circulating MDA, 
a marker of lipid peroxidation, was significantly different between control subjects and patients with 
HF [26]. In addition, MDA plasma levels have been positively correlated not only with the presence 
of HF, but also with New York Heart Association (NYHA) functional class [27]. 
It is worth noting that levosimendan administration to decompensated HF subjects was able to 
improve oxidative damage, as shown by the TBARS measurement, by five days [28]. To date, 
however, the information available about the effects of levosimendan on oxidative stress and cardiac 
systo-diastolic function in cardiogenic shock/low cardiac output patients for ischemic disease, is 
scarce. 
For this reason, in the present study, we aimed to examine, at the same time, the effects of 
intravenous levosimendan treatment on (1) systolic and diastolic functions, (2) hemodynamic 
variables, and (3) oxidant/antioxidant systems, in patients admitted to the cardiothoracic intensive 
care unit (ICU) for cardiogenic shock or decompensated heart failure after coronary artery bypass 
grafting (CABG) or percutaneous transluminal coronary angioplasty (PTCA). To our knowledge, this 
is the first time these parallel assessments have been performed in a clinical setting. 
2. Materials and Methods 
This was a prospective, longitudinal study approved by the Ethical Committee of Azienda 
Ospedaliero Universitaria (AOU) Maggiore della Carità of Novara (655/CE; Studio n. CE 107/17; 
approval date 16/06/2017). All procedures were compliant with the ethical standards of the Helsinki 
Declaration and conformed to standards currently applied in Italy. Patients’ informed written 
consent was collected before starting the study. 
In this pilot study, 4 adult patients admitted to the cardiothoracic ICU of AOU Maggiore della 
Carità of Novara were enrolled. 
Inclusion criteria were: Aged over 18 years, reduced systolic function (ejection fraction, EF, < 
30%) due to cardiogenic shock post-CABG or decompensated heart failure after PTCA. 
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Exclusion criteria: Acute renal or liver failure, septic condition. 
Two male patients underwent CABG for three vessel-diseases. In PTCA patients (one male and 
one female), three arterial grafts were positioned on the left anterior descending coronary artery, and 
intra-aortic balloon pumps (IABP) were used. Demographic data are reported in Table 1. 
Table 1. Demographic data of patients. 
Males/Females 3/1 
Age (years) 63 ± 13.5 
BMI (body mass index) 26.63 ± 1.2 
Diabetes 1/4 
Hypertension 0 
Smoker (>1 cigarette) 0 
Dyslipidemia 0 
Hemodynamic variables were monitored by means of a Swan–Ganz pulmonary artery catheter 
in all patients [29,30]. 
The central venous pressure (CVP), mean pulmonary arterial pressure (PAP), cardiac output 
(CO), cardiac index (CI), systemic vascular resistance index (SVRI), pulmonary vascular resistance 
index (PVRI), and the pulmonary capillary wedge pressure (PCWP) were continuously measured. 
Heart rate (HR), and systolic (SAP) and diastolic (DAP) arterial blood pressure were also recorded. 
Arterial and venous oxygen partial pressure (pO2), and arterial and venous oxygen saturation (SO2) 
were examined by hemogasanalyis (Radiometer ABL 90 Flex). 
In all patients, systo-diastolic cardiac function was examined by an expert cardiologist through 
echocardiography (GE Vivid-i), following the time-course reported below, and as recommended by 
international guidelines [31–33]. 
After baseline data evaluation, levosimendan was administered intravenously at the dose of 0.1 
μg/kg/min without a loading dose, which is adopted in the ICU for the treatment of cardiogenic shock 
or low cardiac output patients [34,35]. In all patients, vasopressor support was implemented by 
epinephrine (0.01–0.1 μg/kg/min) and in one patient with dopamine (2 μg/kg/min), as well. 
Mechanically assisted ventilation was provided to CABG patients. 
Venous samples were taken for GSH and TBARS measurements, following the time-course 
reported below. 
2.1. Collection of Samples 
For the determination of GSH and TBARS, 10 mL of blood samples were taken from each donor 
using BD Vacutainer tubes (sodium heparin as anticoagulant). Each sample was immediately 
centrifuged by a refrigerated centrifuge (Eppendorf, mod. 5702 with rotor A-4-38) for 10 min, at a 
speed of 3100 g at 4 °C. The plasma obtained was divided into 5 tubes that were stored at −20 °C at 
the Physiology laboratory of the University of Eastern Piedmont of Novara. 
2.2. GSH Quantification 
GSH measurement was performed by using the Glutathione Assay Kit (Cayman Chemical, Ann 
Arbor, MI, USA), as previously described [36,37]. Each plasma sample was deproteinated by adding 
an equal volume of MPA solution to the sample which was then centrifuged at 2000 g for 2 min. The 
supernatant was collected, and 50 μL/mL of TEAM reagent was added to each sample in order to 
increase the pH. Fifty microliters of the samples were transferred to a 96-well plate where GSH was 
detected following the manufacturer’s instructions through a spectrophotometer (VICTOR™ X 
Multilabel Plate Reader), at excitation/emission wavelengths of 405–414 nm. Glutathione was 
expressed as μM. The measurements were performed in triplicate. 
2.3. TBARS Quantification 
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TBARS were determined as MDA release. The MDA measurement was performed by using the 
TBARS assay Kit (Cayman Chemical), as previously [36,38]. For the assays, 100 μL of each plasma 
sample was added to 100 μL of sodium dodecyl sulfate (SDS) solution and 2 mL of the Color Reagent, 
following the manufacturer’s instructions. Each sample was boiled for 1 h and then transferred to ice 
for 10 min in order to stop the reaction. Each sample was centrifuged for 10 min at 1600 g at 4 °C and 
150 μL was transferred to a 96-well plate where MDA was detected following the manufacturer’s 
instructions through a spectrophotometer (VICTOR™ X Multilabel Plate Reader), at 
excitation/emission wavelengths of 530–540 nm. MDA production was expressed in μM. The 
measurements were performed in triplicate. 
2.4. Time-Course of Measurements 
T0, before the beginning of levosimendan administration: Hemodynamic variable 
measurements and cardiac systo-diastolic evaluation, GSH and TBARS sampling.  
T1, at the end of 0.1 μg/kg/min levosimendan infusion (duration 24 h): Hemodynamic variable 
measurements and cardiac systo-diastolic evaluation, GSH and TBARS sampling. 
T2, 24 h after the end of levosimendan infusion: Hemodynamic variable measurements and 
cardiac systo-diastolic evaluation, GSH and TBARS sampling. 
T3, at 72 h after the end of levosimendan administration: Hemodynamic variable measurements 
and cardiac systo-diastolic evaluation, GSH and TBARS sampling. 
T4, at the end of inotropic support: Hemodynamic variable measurements and cardiac systo-
diastolic evaluation, GSH and TBARS sampling. 
2.5. Statistical Analysis 
All data were recorded using the Institution’s database. Statistical analysis was performed by 
using GraphPad Prism 6.0. Non-nominal variables were checked for normality before statistical 
analysis. ANOVA for repeated measurements was used to compare results obtained in each patient 
at various timings. All non-nominal data were expressed as means ± standard deviation (SD). A p 
value lower than 0.05 was taken for statistical significance. 
3. Results 
The patients were overweight, and one patient was diabetic, but major cardiovascular risk 
factors like hypertension, smoking, or dyslipidemia were not identified (Table 1). At T0, mean EF 
amounted to 25%. In the two patients who underwent cardiothoracic surgery, extracorporeal 
circulation lasted 145 ± 21 min.  
Improvements were recorded in CO, CI, and SAP, as shown in Figure 1 and Figure 2A,B. 




Figure 1. In (A,B), effects of levosimendan on cardiac output (CO) and in (C,D), on cardiac index (CI). 
In A and C, values are means ± SD. In B and D, columns represent single patients. * p < 0.05 vs. T0. 




Figure 2. In (A,B), effects of levosimendan on systolic (SAP) and in (C,D), diastolic (DAP) arterial 
blood pressure. In A and C, values are means ± SD. In B and D, columns represent single patients. * p 
< 0.05 vs. T0. 
EF increased from mean 26.25% ± 2.2 to 43.7% ± 2.9 at early T2, and to 48% ± 1.4 at T4 (p < 0.05). 
A reduction of CVP, pulmonary capillary wedge pressure (wedge), and PVRI was also observed 
(Figures 3A,B and Figures 4B,D). PAP at T4 was lower than PAP at T0 (Figure 3C,D).  




Figure 3. In (A,B), effects of levosimendan on central venous pressure (CVP) and in (C,D) on mean 
pulmonary arterial pressure (PAP). In A and C, values are means ± SD. In B and D, columns represent 
single patients. * p < 0.05 vs. T0. 




Figure 4. In (A,B), effects of levosimendan on pulmonary capillary wedge pressure (wedge) and in 
(C,D), on pulmonary vascular resistance index (PVRI). In A and C, values are means ± SD. In B and 
D, columns represent single patients. * p < 0.05 vs. T0. 
Indices of diastolic function (E/E’, E/A) were improved by levosimendan administration (E to 
early diastolic mitral annular tissue velocity, E/, from mean 14.5 ± 1.3 at T0, to mean 11 ± 1.4 at T2, to 
mean 6.7 ± 1.7 at T4; early to late diastolic transmitral flow velocity, E/A, from >1 at T0 to <1 at T4; p 
< 0.05). No significant changes of HR were observed (mean values at T0 to T4, respectively: 96.75, 
90.75, 95.75, 88, 91 beats/min), nor in DAP (Figure 2C,D). In the two PTCA patients, IABP was 
removed at T2 and mechanical ventilation was suspended after 1 and 3 days, respectively. In all 
patients, epinephrine was reduced from mean 0.06 ± 0.04 μg/kg/min at T0, to 0.04 ± 0.02 μg/kg/min 
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at T2, to 0.001 ± 0.009 μg/kg/min at T3; at T4 it was suspended. Dopamine was reduced from 2 
μg/kg/min at T0, to 1 μg/kg/min at T2; at T4 it was suspended. 
Arterial oxygen saturation and oxygen partial pressure amounted to about 98% and 96 mmHg 
at T0 and did not vary significantly throughout the time-course (Figure 5). 
 
Figure 5.  In (A,B), effects of levosimendan on arterial partial pressure (pO2) and in (C,D), on arterial 
oxygen saturation (SO2). In A and C, values are means ± SD. In B and D, columns represent single 
patients. 
ygen venous partial pressure and venous oxygen saturation amounted to about 37 mmHg and 
63% at T0 and did not show any changes (Figure 6). 




Figure 6. In (A,B), effects of levosimendan on venous oxygen partial pressure (pO2) and in (C,D), on 
venous oxygen saturation (SO2). In A and C, values are means ± SD. In B and D, columns represent 
single patients. 
As depicted in Figure 7, at T0, the levels of GSH and MDA were 0.21 ± 0.16 μM and 7.1 ± 1.9 μM, 
respectively. Immediately after levosimendan administration, an improvement of the above 
parameters was observed. GSH at T1 rose to 1.16 ± 0.5 μM, whereas MDA declined to 4.3 ± 1.1 μM 
(both p < 0.05 vs. T0). At T2, T3, and T4, the levels of GSH increased (3.1 ± 1.3; 3.8 ± 1.2; 2.8 ± 1.2 μM, 
respectively; all p < 0.05 vs. T0) and those of MDA decreased progressively (2.5 ± 0.9; 2.4 ± 0.9; 2.1 ± 
0.8 μM; all p < 0.05 vs. T0). 




Figure 7. In (A,B), effects of levosimendan on plasma glutathione (GSH) and in (C,D), on plasma 
malonyldialdeide (MDA) concentration. In A and C, values are means ± SD. In B and D, columns 
represent single patients. * p < 0.05 vs. T0. 
4. Discussion 
The results obtained in the present study show protective effects elicited by levosimendan 
administration in cardiogenic shock or low cardiac output patients post-CABG or PTCA, through the 
modulation of oxidant/antioxidant balance. 
The balance between ROS production and their removal by antioxidant systems is described as 
the “redox state”. Oxidative stress arises any time the production of ROS exceeds the levels of 
antioxidants. In HF, an increased production of ROS, originating mainly by mitochondria from failing 
hearts, has been widely evidenced [39]. Chronic increases in ROS production may lead to a cycle of 
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mitochondrial DNA damage, leading to a functional decline, further ROS generation, and cellular 
injury. ROS can directly impair contractile function by modifying proteins central to excitation–
contraction coupling, ion transporters, and Ca2+ cycling, as well [40]. 
It is noteworthy that cardiac oxidative stress has been associated with diastolic dysfunction, as 
well [41], via changes in Ca2+ handling. Hence, increased ROS production can impair the activity of 
Ca2+/calmodulin kinase (CaMK) II or SERCA2, or affect Ca2+ sensitivity of myofilaments. As a result, 
a diastolic SR Ca2+ leak and a reduction of relaxation stiffness of cardiomyocytes would happen [42]. 
In addition, changes of mitochondrial function could lead to increased intracellular Ca2+, 
resulting in cardiomyocyte super-contracture, disruption of plasmalemma and therefore necrotic cell 
death. Although it was not clearly shown, at the basis of the above effects there could be the increased 
mitochondrial ROS generation [43]. 
Furthermore, KATP channels could represent a target for ROS in HF [44]. It has been shown that 
ROS-dependent modification of mitochondrial KATP channels, in particular, could represent a 
feedback mechanism for the regulation of mitochondrial KATP channel activity itself. Moreover, KATP 
channels have been widely shown to play important roles in protection of the heart from ischemic 
injury [45]. The opening of KATP channels could contribute to the regulation of cardiac mitochondrial 
function [46] and cardioprotection induced by ischemic preconditioning, as well. 
For this reason, any factor able to affect KATP channel activity could represent a rescue method 
against cardiac damage. 
The mechanisms of action of levosimendan are mainly related to the increase of Ca2+ sensitivity 
of troponin C and the opening of KATP channels in myocardium and vessels. Being a calcium sensitizer 
and not a calcium mobilizer, levosimendan does not increase myocardial oxygen consumption nor 
prevent myocardial apoptosis and remodeling [1]. 
For those reasons, levosimendan is widely used for the treatment of low cardiac output 
conditions for its effects on systemic and pulmonary hemodynamics and for the relief of symptoms 
of HF [47]. 
Recent evidence indicates that levosimendan could reduce oxidative markers and increase the 
antioxidant system. In decompensated HF patients, a reduction of TBARS levels was observed after 
5 days from the start of levosimendan administration [28], while, in the animal model of renal and 
liver ischemia/reperfusion plasma, TBARS and GSH concentration was restored by levosimendan 
infusion [20,21]. A role for the modulation of the “redox state”, as a possible mechanism of action of 
levosimendan in the protection against HF, might therefore be hypothesized. 
In our study, the infusion of levosimendan in cardiogenic shock or low cardiac output patients 
post-CABG or PTCA improved GSH and reduced TBARS early at the achievement of the therapeutic 
levosimendan dosage. Those effects preceded those on hemodynamics and cardiac systo-diastolic 
function, which were evidenced by the improvement of EF, CO, CI, E/E’, and E/A. 
Our data confirm previous data about the protective effects exerted by levosimendan against 
peroxidation, and highlight their potential as further mechanisms through which levosimendan 
could exert its action on cardiac function. Although it was not examined, the maintenance of 
mitochondria function by levosimendan could be presumed to play a role in its antioxidant effects. 
Hence, mitochondria have emerged as a central factor in the pathogenesis and progression of 
HF. It is widely accepted that mitochondrial dysfunction can contribute to impaired myocardial 
energetics and increased oxidative stress in cardiomyopathies, cardiac ischemic damage, and HF. 
Mitochondrial permeability transition pore opening has been shown to act as a critical trigger of 
myocyte death and myocardial remodeling. Increased mitochondrial permeabilization is a 
mechanistic pathway at the basis of myocardial apoptosis [48]. 
Previous findings have evidenced that levosimendan is able to prevent the fall of mitochondrial 
membrane potential and transition pore opening in cardiomyocytes [49]. In this way, it could 
modulate ROS release and apoptotic signaling. Thus, it could be hypothesized that the keeping 
mitochondrial function by levosimendan could represent the starting mechanism for the reduction 
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of ROS release and the restoration of myocardial energetics and cell viability. These events would be 
followed by the improvement of cardiac systole and diastole and hemodynamics. 
In conclusion, the results obtained have shown that levosimendan improved GSH and reduced 
TBARS early before the onset of the cardiovascular effects. 
The main limitation of this study is the low number of patients and the different etiologies. 
However, the aim of this pilot study was to evaluate if levosimendan could exert its protective effects 
in patients with cardiac low output syndrome or cardiogenic shock on cardiovascular function and 
hemodynamics as a result of its ability to prevent the GSH reduction and TBARS increase, regardless 
of the etiology. Moreover, no comparison was performed with a “control” group. However, in this 
study, all patients were in control of themselves and we analyzed, at different time points, the 
concomitant changes of hemodynamic variables and cardiac systo-diastolic function, as well as the 
changes in the levels of oxidants and antioxidants. The results obtained have shown that 
levosimendan improved GSH and reduced TBARS early before the onset of the cardiovascular 
effects. Thus, in spite of the low number of cases, levosimendan infusion was able to significantly 
exert beneficial effects on both the oxidant and antioxidant system, hemodynamics, and cardiac 
function in cardiogenic shock/low cardiac output patients. A larger number of cases will be necessary 
to perform a more detailed analysis of the protective effects of levosimendan and evaluation of any 
differences among various patients. 
Overall, the results obtained in this pilot study set the rationale for a clinical trial in a larger 
population, whose number will be established through a power calculation, and stratified for age, 
sex, BMI, comorbidities, and etiologies. In this regard, the role of IABP as a modulator of oxidative 
stress could be further analyzed. In addition, it would be interesting to collect more data about the 
“redox state” and inflammation and compare the effects of levosimendan with those of other 
inotropes. 
Finally, it seems important to follow the putative anti-inflammatory effects of this drug, not only 
in cardiac patients, but also in patients with conditions such as pulmonary hypertension or 
amyotrophic lateral sclerosis, in which levosimendan is currently being clinically evaluated [50,51]. 
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